Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul;84(1):54-9.
doi: 10.1532/IJH97.06016.

Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3

Affiliations

Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3

Hideaki Nakajima et al. Int J Hematol. 2006 Jul.

Abstract

Internal tandem duplication of FLT3 tyrosine kinase (FLT3-ITD) is the most prevalent mutation found in acute myelogenous leukemia (AML), having been identified in 20% to 30% of all AML patients. We have previously shown that FLT3-ITD signals mainly through the signal transducer and activator of transcription 5 (STAT5) pathway and have suggested the possible involvement of Tyk2 in STAT5 activation by FLT3-ITD. The present study addressed the role of Tyk2 in FLT3-ITD signaling in a murine bone marrow transplantation (BMT) model. Transplantation of wild-type bone marrow cells transduced with the FLT3-ITD gene induced lethal myeloproliferative disease (MPD) in the recipient mice at a median latency of 89 days. Interestingly, some mice presented the proliferation of B- or T-lymphoid blasts in various organs, a presentation that resembled acute lymphoblastic leukemia (ALL). Mice that received Tyk2-deficient bone marrow cells transduced with FLT3-ITD developed lethal MPD with a disease latency (median, 100 days) and pathologic picture similar to those of mice that received wild-type bone marrow cells. These results indicate that (1) Tyk2 is not essential for MPD induction by FLT3-ITD and (2) FLT3-ITD by itself can induce ALL in a murine BMT model.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Invest. 2005 Apr;115(4):919-29 - PubMed
    1. Leukemia. 1999 Jan;13(1):38-43 - PubMed
    1. Br J Haematol. 2001 Jun;113(4):983-8 - PubMed
    1. Blood. 2002 Jun 15;99(12):4326-35 - PubMed
    1. Leukemia. 1996 Dec;10(12):1911-8 - PubMed

Publication types

MeSH terms

LinkOut - more resources